

Financial news for LPCN dated on 2020-05-27: HC Wainwright & Co. Maintains Buy on Lipocine, Raises Price Target to \$3

Financial news for LPCN dated on 2020-05-18: Shares of several healthcare companies are trading higher in sympathy with the overall market as optimism around a coronavirus vaccine increased following news from Moderna.

Financial news for LPCN dated on 2020-05-15: Lipocine Announces Presentations On TLANDO At AUA Virtual Experience 2020 May 15-17

Financial news for LPCN dated on 2020-05-13: Lipocine Highlights Results Of Pre-Clinical Study Of LPCN 1144

Financial news for LPCN dated on 2020-05-07: Shares of several healthcare companies are trading higher amid continued economic optimism as some US states ease lockdown restrictions. While jobless claims came in worse than estimates, figures were lower than in prior weeks.

Financial news for LPCN dated on 2020-05-07: Lipocine Q1 EPS \$(0.140), Same YoY

Financial news for LPCN dated on 2020-05-05: Lipocine Reports FDA Clears LPCN 1148 Investigational New Drug Application For Phase 2 Cirrhosis Trial

Financial news for LPCN dated on 2020-04-17: Lipocine Announces FDA Has Denied Oral Testosterone Ester Citizen Petition Filed By Clarus Therapeutics

Financial news for LPCN dated on 2020-04-09: Lipocine Reports US Appeals Court Affirmed Decision By Patent Trial, Appeal Board

Financial news for LPCN dated on 2020-03-26: Lipocine Says 'No ultimate determination of infringement or validity of the patents has been determined at this point.' In Patent Infringement Suit Against Clarus

Financial news for LPCN dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for LPCN dated on 2020-03-13: Lipocine Q4 EPS \$(0.5) Up From \$(0.55) YoY

Financial news for LPCN dated on 2020-03-04: Lipocine Announces TLANDO PDUFA Date Of August 28, 2020

Financial news for LPCN dated on 2020-02-26: 24 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for LPCN dated on 2020-02-25: Lipocine shares are trading lower after the company announced a registered direct offering of 10.08 million units priced at \$0.595 per unit.

Financial news for LPCN dated on 2020-02-25: Lipocine Reports \$6M Registered Direct Offering Priced At The Market: ~10.08M Class A Units Priced At \$0.595/Unit

Financial news for LPCN dated on 2020-02-24: Lipocine Says the FDA is Satisfied with its Approach to Collect Data for the Resubmission of TLANDO

Financial news for LPCN dated on 2020-02-19: Lipocine Receives Patent Titled 'Testosterone undecanoate compositions'

Financial news for LPCN dated on 2020-02-11: Lipocine Reports Voluntary Dismissal Of Allegations Of Patent Infringement for Expired US Patents '463, '988 Related To Clarus Therapeutics

Financial news for LPCN dated on 2020-02-06: Lipocine 13G Filing From Hudson Bay Capital Shows 9.99% Stake

Financial news for LPCN dated on 2020-01-27: 20 Specialty & Generic Drug Manufacturer Stocks Moving In Monday's Session

Financial news for LPCN dated on 2020-01-23: 14 Drug Manufacturers--Specialty & Generic Stocks Moving In Thursday's Session

Financial news for LPCN dated on 2020-01-22: 18 Drug Manufacturers--Specialty & Generic Stocks Moving In Wednesday's Session

Financial news for LPCN dated on 2020-01-07: 20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for LPCN dated on 2020-01-06: 20 Healthcare Stocks Moving In Monday's

Pre-Market Session

Financial news for LPCN dated on 2020-01-02: Lipocine Chairman Patel Buys 40,000 @ \$0.38

Financial news for LPCN dated on 2019-12-27: Lipocine Received Notice From Nasdaq Stating Bid Price Of Common Stock For Last 30 Trading Days Closed Below Requirement

Financial news for LPCN dated on 2019-12-17: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

Financial news for LPCN dated on 2019-12-16: Stocks That Hit 52-Week Lows On Monday

Financial news for LPCN dated on 2019-12-13: Stocks That Hit 52-Week Lows On Friday

Financial news for LPCN dated on 2019-12-13: The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer

Financial news for LPCN dated on 2019-12-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for LPCN dated on 2019-12-12: The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win

Financial news for LPCN dated on 2019-12-11: 13 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for LPCN dated on 2019-11-22: Lipocine 13G Filing From Sabby Shows New 8.74% Stake

Financial news for LPCN dated on 2019-11-17: The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down

Financial news for LPCN dated on 2019-11-15: The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

Financial news for LPCN dated on 2019-11-15: 70 Biggest Movers From Yesterday

Financial news for LPCN dated on 2019-11-14: Mid-Afternoon Market Update: Contura Energy Drops Following Q3 Results; International Game Technology Shares Surge

Financial news for LPCN dated on 2019-11-14: 48 Stocks Moving In Thursday's Mid-Day Session

Financial news for LPCN dated on 2019-11-14: Mid-Day Market Update: Opera Rises After Strong Q3 Results; LiqTech International Shares Fall

Financial news for LPCN dated on 2019-11-14: Stocks That Hit 52-Week Lows On Thursday

Financial news for LPCN dated on 2019-11-14: Lipocine Prices Offering Of 10.45M Class A Units And 1.55M Class B Units At \$0.50/Class A Unit And \$0.4999/Class B Unit

Financial news for LPCN dated on 2019-11-14: The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

Financial news for LPCN dated on 2019-11-14: 19 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for LPCN dated on 2019-11-14: 30 Stocks Moving in Thursday's Pre-Market Session

Financial news for LPCN dated on 2019-11-14: 11 Stocks To Watch For November 14, 2019

Financial news for LPCN dated on 2019-11-13: Lipocine shares are trading lower after the company reported a common stock offering of no disclosed size.

Financial news for LPCN dated on 2019-11-13: Lipocine Reports Offering Of Common Stock, Warrants, No Size Disclosed

Financial news for LPCN dated on 2019-11-12: Lipocine Q3 EPS \$(0.12), Same YoY

Financial news for LPCN dated on 2019-11-12: 6 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for LPCN dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for LPCN dated on 2019-11-12: 58 Biggest Movers From Yesterday

Financial news for LPCN dated on 2019-11-11: Mid-Afternoon Market Update: Qurate Retail Gains On Upbeat Earnings; ASLAN Pharmaceuticals Shares Slide

Financial news for LPCN dated on 2019-11-11: 38 Stocks Moving In Monday's Mid-Day Session

Financial news for LPCN dated on 2019-11-11: Mid-Day Market Update: Carbonite Jumps Following Acquisition News; Lipocine Shares Plummet

Financial news for LPCN dated on 2019-11-11: Stocks That Hit 52-Week Lows On Monday

Financial news for LPCN dated on 2019-11-11: Mid-Morning Market Update: Markets Open Lower; SunPower To Receive \$298 Million Equity In Company Split

Financial news for LPCN dated on 2019-11-11: Lipocine's Male Hormone Therapy Stumbles With FDA For The Third Time

Financial news for LPCN dated on 2019-11-11: Benzinga Pro's Top 5 Stocks To Watch For Mon., Nov. 11, 2019: WBA, LPCN, NXTC, SPWR, TME

Financial news for LPCN dated on 2019-11-11: Lipocine Receives Complete Response Letter from the FDA for its New Drug Application for TLANDO, FDA Says the Efficacy Trial Did Not Meet the Three Secondary Endpoints for Maximal Testosterone Concentrations

Financial news for LPCN dated on 2019-11-03: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Financial news for LPCN dated on 2019-11-01: 17 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for LPCN dated on 2019-11-01: Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

Financial news for LPCN dated on 2019-10-28: 51 Biggest Movers From Friday

Financial news for LPCN dated on 2019-10-17: 54 Biggest Movers From Yesterday

Financial news for LPCN dated on 2019-10-16: 44 Stocks Moving In Wednesday's Mid-Day Session

Financial news for LPCN dated on 2019-09-12: 71 Biggest Movers From Yesterday

Financial news for LPCN dated on 2019-09-09: Stocks That Hit 52-Week Highs On Monday

Financial news for LPCN dated on 2019-09-05: Stocks That Hit 52-Week Highs On Thursday

Financial news for LPCN dated on 2019-09-04: The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

Financial news for LPCN dated on 2019-08-27: Lipocine Announces Patent Infringement Trial With Clarus Will Begin Aug. 4 2020

Financial news for LPCN dated on 2019-08-26: Lipocine Withdraws Preliminary Injunction Threat Against Marketing Of Clarus Therapeutics' Jatenzo Product, Trial Date Set For August 2020

Financial news for LPCN dated on 2019-08-23: Stocks That Hit 52-Week Highs On Friday

Financial news for LPCN dated on 2019-08-22: Stocks That Hit 52-Week Highs On Thursday

Financial news for LPCN dated on 2019-08-22: The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

Financial news for LPCN dated on 2019-08-22: 60 Biggest Movers From Yesterday

Financial news for LPCN dated on 2019-08-07: Lipocine Q2 EPS \$(0.14) Beats \$(0.16) Estimate

Financial news for LPCN dated on 2019-07-23: Lipocine Receives FDA Clearance For Clinical Testing Of Its NASH Candidate, LPCN 1144, In Expanded Target Population

Financial news for LPCN dated on 2019-06-28: 18 Stocks Joining The Russell Indices

Financial news for LPCN dated on 2019-06-25: Lipocine Set To Join Russell Microcap Index , Effective Jul. 1

Financial news for LPCN dated on 2019-05-14: Lipocine Announces TLANDO NDA PDUFA Action Date Of November 9, 2019

Financial news for LPCN dated on 2019-05-08: Lipocine Q1 EPS \$(0.14), Inline

Financial news for LPCN dated on 2019-04-15: 48 Biggest Movers From Friday

Financial news for LPCN dated on 2019-04-03: Clarus Therapeutics Has Refuted Patent Infringement Complaint By Lipocine

Financial news for LPCN dated on 2019-04-03: Lipocine Seeks An Injunction Against The Marketing Of Clarus Therapeutics' Jatenzo For Testosterone Replacement Therapy

Financial news for LPCN dated on 2019-03-27: Lipocine Shares Tick Lower As Traders Circulate FDA Access Data Doc Showing Approval For Competitor Clarus Therapeutics' Jatenzo

Financial news for LPCN dated on 2019-03-27: Lipocine Announces ABPM Labeling Study Results Consistent With Recently Approved Testosterone Replacement Therapy

Financial news for LPCN dated on 2019-03-26: Lipocine Reports Acceptance Of Abstract Of Late-Breaker Presentation On LPCN 1144 Results As Part Of EASL

Financial news for LPCN dated on 2019-03-14: Lipocine Reports Has Been Selected To Present LPCN 1144 Results at ENDO 2019

Financial news for LPCN dated on 2019-03-14: 68 Biggest Movers From Yesterday

Financial news for LPCN dated on 2019-03-13: 48 Stocks Moving In Wednesday's Mid-Day Session

Financial news for LPCN dated on 2019-03-13: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning Of Wed., Mar. 13, 2019

Financial news for LPCN dated on 2019-03-12: Benzinga Pro's Top 10 Most-Searchd Tickers For Afternoon Of Tues., Mar. 12, 2019

Financial news for LPCN dated on 2019-03-12: Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate

Financial news for LPCN dated on 2019-03-12: Lipocine shares are trading higher after the company announced that its LPCN 1144 NASH Therapy demonstrated substantial fatty liver resolution and meaningful liver fat reduction in a 16-week liver fat study.

Financial news for LPCN dated on 2019-03-12: Lipocine's LPCN 1144 For NASH Demonstrated Substantial Fatty Liver Resolution And Meaningful Liver Fat Reduction In 16-Week Liver Fat Study

Financial news for LPCN dated on 2019-03-12: Lipocine Announces Its LPCN 1144 NASH Therapy Demonstrated Substantial Fatty Liver Resolution And Meaningful Liver Fat Reduction In NAFLD Population

Financial news for LPCN dated on 2019-03-06: Lipocine Q4 EPS \$(0.55) Misses \$(0.13) Estimate, Sales \$428.031K

Financial news for LPCN dated on 2019-02-14: Lipocine Inc. Rpoerts FDA Clearance Of IND to Commence Phase 2 Study Of LPCN 1144 In Biopsy Confirmed NASH Subjects

Financial news for LPCN dated on 2019-01-24: 51 Stocks Moving In Thursday's Mid-Day Session

Financial news for LPCN dated on 2019-01-24: Lipocine shares are trading higher after the company filed an Investigational New Drug Application to initiate a Phase 2 2 study of LPCN 1144 in NASH subjects.

Financial news for LPCN dated on 2019-01-24: Lipocine 8-K Shows Co. Filed Investigational New Drug Application To Initiate Phase 2 Study Of LPCN 1144 In NASH With Biopsy-Confirmed NASH Subjects

Financial news for LPCN dated on 2019-01-18: 48 Biggest Movers From Yesterday

Financial news for LPCN dated on 2019-01-17: Mid-Afternoon Market Update: Dow Turns Higher; Signet Jewelers Shares Plunge

Financial news for LPCN dated on 2019-01-17: 34 Stocks Moving In Thursday's Mid-Day Session

Financial news for LPCN dated on 2019-01-17: Mid-Day Market Update: Insteel Industries Falls After Q1 Results; Lipocine Shares Jump

Financial news for LPCN dated on 2019-01-17: Ladenburg Thalmann Is Encouraged By Lipocine's 'Positive interim LPCN 1144 proof-of-concept NASH study data showing a reduction on liver fat based on MRIs'; Reiterates Buy, \$5 Target

Financial news for LPCN dated on 2019-01-17: 'Lipocine fatty liver drug study results don't hold up to scrutiny' -STAT News

Financial news for LPCN dated on 2019-01-17: Mid-Morning Market Update: Markets Mostly Lower; Morgan Stanley Earnings Miss Estimates

Financial news for LPCN dated on 2019-01-17: Lipocine's NASH Candidate Shows Promise In Liver Fat Study

Financial news for LPCN dated on 2019-01-17: Lipocine shares are trading higher after the company gave an update on its liver fat study.

Financial news for LPCN dated on 2019-01-17: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for LPCN dated on 2019-01-17: Adam Feuerstein Bearish Tweet on Lipocine: I could conduct another webinar on clinical trial red flags based solely on today's \$LPCN... Missing patients (and too few overall), no placebo control, skewed means, arbitrary data cutoffs... VKTX data way better

Financial news for LPCN dated on 2019-01-17: Lipocine's NASH Therapy Candidate Achieves 'Meaningful' Liver Fat Reduction Based on Interim Results

Financial news for LPCN dated on 2019-01-14: USPTO Grants Priority Motion To Lipocine And Enters Judgment Against Clarus

Financial news for LPCN dated on 2018-12-31: Lipocine Reports Successful Ex Vivo Conversion Assessment Of TLANDO

Financial news for LPCN dated on 2018-11-07: Lipocine Q3 EPS \$(0.12) Beats \$(0.24) Estimate

Financial news for LPCN dated on 2018-11-05: Lipocine Announces Completion Of Enrollment In LPCN 1144 Liver Imaging Study In Subjects At-Risk For NASH

Financial news for LPCN dated on 2018-11-01: Lipocine Announces Completion of Enrollment in Ambulatory Blood Pressure Study for TLANDO

Financial news for LPCN dated on 2018-08-07: Lipocine Q2 EPS \$(0.15) Beats \$(0.25) Estimate

Financial news for LPCN dated on 2018-06-07: Lipocine Announces Dosing Of First Subject In Ambulatory Blood Pressure Study For TLANDO Testosterone Replacement Therapy

Financial news for LPCN dated on 2018-05-10: Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Financial news for LPCN dated on 2018-05-09: Lipocine Shares Down 35.4% After The FDA Issued Complete Response Letter Saying Co.'s TRT Product TLANDO Could Not Be Approved In Current Form; FDA Identified 4 Deficiencies

Financial news for LPCN dated on 2018-05-09: Lipocine's Regulatory Hiccups Continue: Testosterone Drug Issued Complete Response Letter, Stock Tanks

Financial news for LPCN dated on 2018-05-09: Benzinga Pro's 5 Stocks To Watch Today

Financial news for LPCN dated on 2018-05-09: UPDATE: Lipocine Says FDA's CRL Advised New Drug Application For TLANDO Cannot Be Approved In Its Present Form; CRL Identified 4 Deficiencies

Financial news for LPCN dated on 2018-05-09: Lipocine Reports Received Complete Response Letter For TLANDO

Financial news for LPCN dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for LPCN dated on 2018-05-08: REMINDER: Lipocine Has FDA PDUFA Date for LPCN 1021 NDA

Financial news for LPCN dated on 2018-05-07: Lipocine Shares Up 3.9% After Co.

Earlier Reported Lighter-Than-Expected Q1 Loss, With FDA PDUFA Date Scheduled For its LPCN 1021 NDA Tuesday

Financial news for LPCN dated on 2018-05-07: The Week Ahead: Nvidia And Dropbox Earnings, April Retail Sales, Trump Drug Pricing Speech Expected

Financial news for LPCN dated on 2018-05-07: Lipocine Q1 EPS \$(0.13) Beats \$(0.21) Estimate

Financial news for LPCN dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for LPCN dated on 2018-05-01: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Financial news for LPCN dated on 2018-03-29: Seaport Global Initiates Coverage On Lipocine with Buy Rating, Announces \$10.00 Price Target

Financial news for LPCN dated on 2018-03-12: Lipocine Reports FY EPS \$(1.05) vs \$(1.03) Est., No Sales

Financial news for LPCN dated on 2018-02-28: Benzinga Pro's Top 10 Most-Searchd Tickers Wed. Morning: Square, Lipocine, Macy's, Mallinckrodt, Tetrphase Pharma, Zosano Pharma, Arcadia Biosciences, DelMar Pharma, Akers Biosciences, Acorn

Financial news for LPCN dated on 2018-02-27: Empire Asset Assigns Penny Stock Lipocine \$21 Price Target, Buy Rating

Financial news for LPCN dated on 2018-02-27: Lipocine Shares Up 12.3% For Session But Well Off Pre-Market High After Empire Asset Management Upgraded Stock To Buy And Set \$21 Price Target

Financial news for LPCN dated on 2018-02-27: Empire Asset Management Upgrades Lipocine to Buy

Financial news for LPCN dated on 2018-02-16: Lipocine Announces Memorandum of Understanding Settlement of Securities Class Action Lawsuit

Financial news for LPCN dated on 2018-01-12: 5 Biggest Price Target Changes For Friday

Financial news for LPCN dated on 2018-01-12: 46 Biggest Movers From Yesterday

Financial news for LPCN dated on 2018-01-11: Adcom Outcome For Lipocine's Testosterone Drug Punctures Stock; Canaccord Downgrades

Financial news for LPCN dated on 2018-01-11: 38 Stocks Moving In Thursday's Mid-Day Session

Financial news for LPCN dated on 2018-01-11: Mid-Day Market Update: Dow Surges 150 Points; Lipocine Shares Plummet

Financial news for LPCN dated on 2018-01-11: Mid-Morning Market Update: Markets Open Higher; Delta Air Lines Tops Q4 Estimates

Financial news for LPCN dated on 2018-01-11: Benzinga's Top Upgrades, Downgrades For January 11, 2018

Financial news for LPCN dated on 2018-01-11: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for LPCN dated on 2018-01-11: Canaccord Genuity Downgrades Lipocine to Hold

Financial news for LPCN dated on 2018-01-10: Lipocine Shares Resume Trade, Plunge 56.6%

Financial news for LPCN dated on 2018-01-10: UPDATE: Lipocine Press Release Confirms FDA AdCom Panel Voted 6 In Favor, 13 Against Benefit/Risk Profile Of TLANDO

Financial news for LPCN dated on 2018-01-10: Lipocine Shares To Resume Trade At 4:50 p.m. EST

Financial news for LPCN dated on 2018-01-10: UPDATE: Lipocine Says FDA Decision On Tlando NDA Expected By Assigned PDUFA Date Of May 8, 2018

Financial news for LPCN dated on 2018-01-10: FDA Votes 6-13 For Benefit/Risk Profile Of Lipocine's Oral Testosterone Product Candidate

Financial news for LPCN dated on 2018-01-10: Benzinga Pro's 6 Stocks To Watch Today

Financial news for LPCN dated on 2018-01-10: Lipocine Shares Halted Ahead Of Adcom Meeting For LPCN 1021

Financial news for LPCN dated on 2018-01-10: Lipocine Shares Halted News Pending

Financial news for LPCN dated on 2018-01-09: REMINDER: Lipocine FDA Adcom Meeting For LPCN 1021 Takes Place Wednesday Jan. 10

Financial news for LPCN dated on 2018-01-08: The Week Ahead: Conferences Take Center Stage, Earnings Begin To Trickle In

Financial news for LPCN dated on 2017-12-30: Attention Biotech Investors: Brace For These January PDUFA Events

Financial news for LPCN dated on 2017-12-08: H.C. Wainwright Assumes Lipocine at Buy, Announces price target \$10.00

Financial news for LPCN dated on 2017-11-17: U.S. FDA Extends Review for Lipocine's TLANDO; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged

Financial news for LPCN dated on 2017-11-08: Lipocine Reports Q3 EPS \$(0.22) vs \$(0.21) Est.

Financial news for LPCN dated on 2017-10-18: Lipocine Reports FDA Scheduled BRUDAC Meeting On Jan. 10, 2018 To Discuss NDA For TLANDO

Financial news for LPCN dated on 2017-09-21: Lipocine Reports PTAB Granted Lipocine's Motion To Deny Clarus' Previously Accorded Priority Date For '428 Patent

Financial news for LPCN dated on 2017-09-20: Lipocine Reports FDA Panel Meeting For TLANDO, Says Date Has Not Been Finalized But Will Occur Prior To PDUFA Goal Date Of Feb. 8, 2018

Financial news for LPCN dated on 2017-08-15: Watch These 5 Huge Put Purchases In Tuesday Trade

Financial news for LPCN dated on 2017-08-14: Lipocine Option Alert: Feb 16 \$5 Puts Sweep (18) at the Ask: 650 @ \$1.851 vs 140 OI; Ref=\$4.22 Signals

Financial news for LPCN dated on 2017-08-14: Lipocine PDUFA Goal Date Set at Feb 8, 2018

Financial news for LPCN dated on 2017-08-07: Lipocine Q2 EPS \$(0.31) vs \$(0.31) Est., No Sales

Financial news for LPCN dated on 2017-06-28: Lipocine Releases Updated Corporate Presentation

Financial news for LPCN dated on 2017-06-26: Lipocine Reports Submission of SPA on LPCN 1107

Financial news for LPCN dated on 2017-06-20: Mid-Afternoon Market Update: Fang Drops After Q1 Results; Invivo Therapeutics Shares Surge

Financial news for LPCN dated on 2017-06-20: 10 Biggest Mid-Day Gainers For Tuesday

Financial news for LPCN dated on 2017-06-20: Mid-Day Market Update: Crude Oil Down Over 3%; Lipocine Shares Spike Higher

Financial news for LPCN dated on 2017-06-20: Lipocine Pops And Drops After LPCN 1021 Meets Primary Endpoint

Financial news for LPCN dated on 2017-06-20: Mid-Morning Market Update: Markets Open Lower; Lennar Tops Q2 Expectations

Financial news for LPCN dated on 2017-06-20: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for LPCN dated on 2017-06-20: Watch These 5 Huge Call Purchases In Tuesday Trade

Financial news for LPCN dated on 2017-06-19: Lipocine +30.5% After-Hours @\$5.25 After Co Announces LPCN 1021 Met Primary Endpoint

Financial news for LPCN dated on 2017-06-19: Benzinga's Option Alert Recap From June 19

Financial news for LPCN dated on 2017-06-19: Lipocine Validates "No Titration" Dosing Regimen, Reports Positive Topline Results For LPCN 1021, Met Primary Endpoints

Financial news for LPCN dated on 2017-06-19: Option Alert: Lipocine Jul 5.0 Calls Sweep: 500 @ ASK \$0.75: 877 traded vs 142 OI: Earnings 8/8 Before Open (est) \$4.02 Ref

Financial news for LPCN dated on 2017-05-08: Lipocine Reports Q1 EPS \$(0.26) vs (0.38) In Prior Year Period

Financial news for LPCN dated on 2017-03-06: Lipocine Reports FY16 EPS \$(1.04) vs. Est. \$(1.16)

Financial news for LPCN dated on 2017-01-11: Royce & Associates Report 6.45% Stake In Lipocine

Financial news for LPCN dated on 2017-01-09: Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107

Financial news for LPCN dated on 2017-01-05: Lipocine Initiates Dosing Flexibility Study For LPCN 1021, Expects Top-Line Results Q2 2017

Financial news for LPCN dated on 2016-12-20: Canaccord Genuity Assumes Lipocine at Buy, Announces \$15.00 Target

Financial news for LPCN dated on 2016-11-08: Lipocine Reports Q3 EPS \$(0.18) vs \$(0.30) Est.

Financial news for LPCN dated on 2016-10-17: Lipocine Gets A Boost After News From The FDA

Financial news for LPCN dated on 2016-10-17: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for LPCN dated on 2016-10-17: Lipocine +10.5% Premarket @\$4.20; FDA Agreed to Review New Dosing Regimen for LPCN 1021

Financial news for LPCN dated on 2016-10-13: Lipocine's Positive Patent Lawsuit News Not Enough To Lift The Stock

Financial news for LPCN dated on 2016-10-13: Clarus Therapeutics Patent Infringement Lawsuit Against Lipocine Dismissed Due To Lack Of FDA Approval For LPCN-1021 And Not On Merits Of Case

Financial news for LPCN dated on 2016-10-11: 14 Stocks Moving In Tuesday's Pre-Market Session

Financial news for LPCN dated on 2016-10-10: Lipocine Still Can't Clear \$6

Financial news for LPCN dated on 2016-10-10: Lipocine Showered With Good News Recently

Financial news for LPCN dated on 2016-10-07: Mid-Afternoon Market Update: Crude Oil Down 1.3%; Ruby Tuesday Shares Fall Following Q1 Results

Financial news for LPCN dated on 2016-10-07: Lipocine Reports Dismissal of Patent Suit Related to LPCN 1021

Financial news for LPCN dated on 2016-10-07: Technical Alert: Liopcine Leaps After New Buy Rating At H.C. Wainwright

Financial news for LPCN dated on 2016-10-07: 10 Biggest Mid-Day Gainers For Friday

Financial news for LPCN dated on 2016-10-07: Mid-Day Market Update: Dow Drops Over 100 Points; Gap Shares Rise Following September Sales Numbers

Financial news for LPCN dated on 2016-10-07: Mid-Morning Market Update: Markets Open Lower; Silicon Motion Raises Q3 Forecast

Financial news for LPCN dated on 2016-10-07: Lipocine Spikes to High of \$5.90 on Volume

Financial news for LPCN dated on 2016-10-07: HC Wainwright's New Buy Rating On Lipocine Suggests 500% Upside

Financial news for LPCN dated on 2016-10-07: H.C. Wainwright Initiates Coverage on Lipocine at Buy, Announces \$25.00 PT

Financial news for LPCN dated on 2016-09-29: 15 Stocks That Rallied 4 Days, Then Sold

Off Yesterday

Financial news for LPCN dated on 2016-09-26: Mid-Afternoon Market Update: Dow Falls 150 Points; Himax Technologies Shares Slide After Nomura Downgrade

Financial news for LPCN dated on 2016-09-26: Mid-Day Market Update: Crude Oil Up 3.3%; Chemtura Shares Surge Following Acquisition News

Financial news for LPCN dated on 2016-09-26: 12 Biggest Mid-Day Gainers For Monday

Financial news for LPCN dated on 2016-09-26: Bio Therapeutic Stocks Strong Today Amid News Out of Array, Lipocine, GW Pharma, Aldeyra: Summit Up 15%, Cerulean 10.5%, Clearside 10%, Aviragen 7.2%, Gemphire, Forward Pharma 5%

Financial news for LPCN dated on 2016-09-26: Lipocine Reports Positive Top-Line Phase 2b Study Results for LPCN 1111, Well Tolerated With No SAE's Reported

Financial news for LPCN dated on 2016-09-20: 30 Stocks With Three-Day Increasing Volume

Financial news for LPCN dated on 2016-08-09: Lipocine Reports Q2 EPS \$(0.32) vs. Est. \$(0.37)

Financial news for LPCN dated on 2016-07-18: Lipocine To Reduce Workforce By 33%

Financial news for LPCN dated on 2016-06-29: Mid-Afternoon Market Update: Dow Jumps Over 250 Points; Diamond Resorts Shares Climb Following Apollo Deal

Financial news for LPCN dated on 2016-06-29: 7 Biggest Mid-Day Losers For Wednesday

Financial news for LPCN dated on 2016-06-29: Mid-Day Market Update: Crude Oil Surges 3%; Galena Biopharma Shares Tumble

Financial news for LPCN dated on 2016-06-29: Stocks Hitting 52-Week Lows

Financial news for LPCN dated on 2016-06-29: Mid-Morning Market Update: Markets Open Higher; General Mills Profit Tops Expectations

Financial news for LPCN dated on 2016-06-29: 13 Stocks Moving In Wednesday's Pre-Market Session

Financial news for LPCN dated on 2016-06-29: Lipocine -51% Premarket @\$3.07 Following Announcement of CRL from FDA

Financial news for LPCN dated on 2016-06-29: Lipocine Receives Response Letter From FDA, Notes Deficiencies In Dosing Algorithm On Label

Financial news for LPCN dated on 2016-06-27: Watch Out For Extreme Volatility In Lipocine On Tuesday

Financial news for LPCN dated on 2016-06-24: The 5 Stocks Wall Street Is Most Confident On This Week

Financial news for LPCN dated on 2016-06-21: Option Alert: LPCN Jul16 7.5 Calls: 1000 @ ASK \$2.05: 1071 traded vs 657 OI: Earnings 8/9 \$6.62 Ref

Financial news for LPCN dated on 2016-06-20: Stocks Hitting 52-Week Lows

Financial news for LPCN dated on 2016-06-17: Slingshot Insights' Expert Conference Call On Lipocine

Financial news for LPCN dated on 2016-06-08: Here's Why You Should Watch For Movement In Lipocine Tomorrow

Financial news for LPCN dated on 2016-05-09: Lipocine Reports Q1 EPS \$(0.38) vs \$(0.33) Est.

Financial news for LPCN dated on 2016-03-28: Lipocine Reports Clinical Data For LPCN 1021 At ENDO 2016 and ASA 41st Annual Conf.

Financial news for LPCN dated on 2016-03-10: Lipocine Reports FY15 EPS \$(1.11) vs. Est. \$(1.12)

Financial news for LPCN dated on 2016-03-04: Lipocine Enters into a Commercial Manufacturing Services and Supply Agreement with M.W. Encap Ltd.

Financial news for LPCN dated on 2016-02-16: Lipocine Reports Positive Results of LPCN 1107 Study for the Prevention of Preterm Birth

Financial news for LPCN dated on 2015-11-16: Benzinga's Volume Movers

Financial news for LPCN dated on 2015-11-13: Benzinga's Volume Movers

Financial news for LPCN dated on 2015-11-13: Morning Market Gainers

Financial news for LPCN dated on 2015-11-12: Lipocine +16% After-Hours on Earnings Beat, Announcement of FDA PDUFA Date of June 28, 2016 to Complete Review of NDA for LPCN-1021

Financial news for LPCN dated on 2015-11-12: Lipocine Reports Q3 EPS \$(0.35) vs \$(0.25) Est.

Financial news for LPCN dated on 2015-11-11: Lipocine Reports Presentation of LPCN 1021 Data at SMSNA Meeting

Financial news for LPCN dated on 2015-10-29: FDA Accepts for Filing Lipocine's New Drug Application for Its Oral Testosterone Replacement Product Candidate, LPCN 1021

Financial news for LPCN dated on 2015-09-28: Lipocine Reports First Subject Dosed in Multi-Dose PK Study for Its Oral Product Candidate for the Prevention of Pre-Term Birth

Financial news for LPCN dated on 2015-08-31: Benzinga's Volume Movers

Financial news for LPCN dated on 2015-08-31: Lipocine Submits New Drug Application to FDA for Its Oral Testosterone Replacement Product Candidate, LPCN 1021

Financial news for LPCN dated on 2015-08-12: Empire Asset Management Raises PT On Lipocine To \$25 From \$18, Cites Lipocine Balance Sheet Strength As Means To 'accelerate its development programs' & Sees Potential For Commercialization Arrangements

Financial news for LPCN dated on 2015-08-11: Lipocine Reports Q2 Loss of \$0.26/Share vs Loss of \$0.20/Share Est.

Financial news for LPCN dated on 2015-07-22: Market Update: Wednesday's Mid-Day Movers: U.S., Asian Markets Slow; Apple, Microsoft, Chipotle, IBM And More

Financial news for LPCN dated on 2015-07-22: Benzinga's Top Initiations

Financial news for LPCN dated on 2015-07-22: Roth Capital Starts Lipocine, Pieris Pharma With Buy Ratings Amid Enormous Market Opportunity

Financial news for LPCN dated on 2015-07-22: Roth Capital Initiates Coverage on Lipocine at Buy

Financial news for LPCN dated on 2015-07-16: Lipocine: Empire Asset Mgmt Says Company Is 'an easy pill to swallow', Initiates Buy With \$18 PT

Financial news for LPCN dated on 2015-07-16: Evercore Partners Initiates Coverage on Lipocine at Buy, Announces \$18.00 PT

Financial news for LPCN dated on 2015-06-29: Lipocine's Oral Testosterone top-line 52-week safety results from its Study of Oral Androgen Replacement pivotal Phase 3 clinical study

Financial news for LPCN dated on 2015-06-23: Benzinga's Top Initiations

Financial news for LPCN dated on 2015-06-23: Canaccord Genuity Initiates Coverage on Lipocine at Buy, Announces \$15.00 PT

Financial news for LPCN dated on 2015-06-15: Lipocine Announces Successful Completion of Food Effect Study for LPCN 1021, an Oral Testosterone Product Candidate

Financial news for LPCN dated on 2015-06-08: Lipocine Announces Development Plans for LPCN 1107

Financial news for LPCN dated on 2015-06-02: Lipocine Attains FDA Orphan Drug Designation for LPCN 1107

Financial news for LPCN dated on 2015-06-02: Lipocine Receives FDA Orphan Drug Designation for LPCN 1107, an Oral Product Candidate for the Prevention of Preterm Birth

Financial news for LPCN dated on 2015-06-02: Lipocine Shares Moving Higher as FDA Issues Orphan Drug Designation for Co.'s Pregnancy Candidate

Financial news for LPCN dated on 2015-05-11: Lipocine to Present Additional LPCN 1021

Clinical Data at American Urological Association Annual Meeting

Financial news for LPCN dated on 2015-04-29: Lipocine Prices Offering of Common Stock at \$6.50/Share

Financial news for LPCN dated on 2015-04-24: Lipocine Prices 4.65M Shares at \$6.50/Share

Financial news for LPCN dated on 2015-04-23: 8-K from Lipocine Shows Registration for Common Stock Offering

Financial news for LPCN dated on 2015-04-23: Lipocine Proposes Stock Offering

Financial news for LPCN dated on 2015-04-10: Lipocine To Present Additional Phase 3 LPCN 1021 Clinical Data at American Society of Andrology 40th Annual Conference

Financial news for LPCN dated on 2015-03-24: Lipocine Announces Results From Pre-NDA Meeting for LPCN 1021, an Oral Testosterone Product Candidate

Financial news for LPCN dated on 2015-03-11: Lipocine Reports FY14 Loss of \$1.60/Share vs Loss of \$1.53/Share Est.

Financial news for LPCN dated on 2015-02-27: Lipocine Announces Presentation of LPCN 1021 Clinical Data at ENDO 2015

Financial news for LPCN dated on 2015-01-30: Lipocine Reports Presentation of LPCN 1107 Clinical Data at SMFM Meeting

Financial news for LPCN dated on 2015-01-12: 8-K from Lipocine Shows Positive Pharmacokinetic Data LPCN 1107, Data Shows Significant HPC Absorption After Oral Administration

Financial news for LPCN dated on 2014-12-15: FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021

Financial news for LPCN dated on 2014-11-19: Lipocine Director Ono Buys 4,000 Shares @\$5.14/Share -Form 4

Financial news for LPCN dated on 2014-11-17: Lipocine Announces CTO Srinivasan Venkateshwaran Will Leave Company; Gerald Simmons Chief Business Development Officer To Leave

Financial news for LPCN dated on 2014-11-14: Lipocine CEO Patel Buys 2,000 Shares @\$5.06/Share -Form 4

Financial news for LPCN dated on 2014-11-13: Lipocine Director Hill Buys 4,000 Shares @\$4.95/Share -Form 4

Financial news for LPCN dated on 2014-11-10: Lipocine Reports Q3 EPS of \$(0.32) vs \$(0.55) Est

Financial news for LPCN dated on 2014-10-13: US Stock Futures Signal Higher Start On Wall Street

Financial news for LPCN dated on 2014-10-13: Lipocine Announces Positive Top-Line Results In Phase 2a Study Of LPCN

Financial news for LPCN dated on 2014-10-01: S-3 from Lipocine Shows Registration for \$100M Mixed Securities Shelf Offering

Financial news for LPCN dated on 2014-09-24: Morning Market Movers

Financial news for LPCN dated on 2014-09-24: Lipocine Announces Positive Top-Line Results In Its Phase 3 Study of LPCN 1021 For Oral Testosterone Replacement Therapy

Financial news for LPCN dated on 2014-09-24: Benzinga's Top #PreMarket Gainers

Financial news for LPCN dated on 2014-09-18: Shares of Lipocine Resume Trade, Stock Down 22.5%

Financial news for LPCN dated on 2014-09-18: Shares of Lipocine Just Halted on Circuit Breaker, Stock Down 19.6%

Financial news for LPCN dated on 2014-09-17: Shares of Lipocine Open for Trade, Not Yet Seeing an Updated Last Price

Financial news for LPCN dated on 2014-09-17: Shares of Lipocine to Resume Trade at 6:30 p.m. EDT

Financial news for LPCN dated on 2014-09-17: FDA Spokesperson Confirms FDA Advisory Panel Has Voted 20-1 FDA Should Revise Approved Uses of Testosterone Treatments

Financial news for LPCN dated on 2014-09-17: Several Sources on Twitter Suggesting FDA Advisory Panel Has Voted 20-1 FDA Needs to Revise Approved Uses for Testosterone Drugs

Financial news for LPCN dated on 2014-09-17: Lipocine Inc Halted: Feds Eye Safety, Efficacy Of Testosterone

Financial news for LPCN dated on 2014-09-17: Lipocine Halted: Pending News

Financial news for LPCN dated on 2014-09-08: Lipocine Announces First Patient Dosed In Phase 1 Study In Pregnant Women Of LPCN 1107, Potentially The First Oral Product For The Prevention Of Preterm Birth

Financial news for LPCN dated on 2014-08-13: Lipocine Reports Q2 EPS of \$(0.55) vs \$(0.42) Est

Financial news for LPCN dated on 2014-07-15: Lipocine Announces Issuance Of U.S. Patent For LPCN 1021

Financial news for LPCN dated on 2014-05-27: Lipocine Announces First Patient Dosed in Phase 2a Study of LPCN 1111, a Novel Testosterone Ester for Oral Testosterone Replacement Therapy

Financial news for LPCN dated on 2014-05-27: Stocks Hitting 52-Week Lows

Financial news for LPCN dated on 2014-05-15: Lipocine Releases Successful Phase 1 1107 Results

Financial news for LPCN dated on 2014-05-15: Lipocine Announces Successful Phase 1 LPCN 1107 Results

Financial news for LPCN dated on 2014-05-13: Lipocine Reports Q1 Loss of \$0.41/Share